Acute Myeloid Leukemia Registry (AMLREGISTRY)

July 29, 2023 updated by: Turkish Hematology Association

Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey
      • Antalya, Turkey
        • Recruiting
        • Antalya Training and Research Hospital
        • Contact:
          • Volkan Karakus
        • Contact:
        • Principal Investigator:
          • Volkan Karakus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All AML patients diagnosed after 1 Jan 2020 will be included to this study.

Description

Inclusion Criteria:

  • Diagnosed as AML after 1 Jan 2020
  • Patients signed informed consent form

Exclusion Criteria:

  • Patients under 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: 60 months
From diagnosis to exits by any cause
60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Turkish Hematology Association

Investigators

  • Study Director: Ilker Kurkcu, Sentez CRO

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 21, 2021

Primary Completion (Estimated)

December 21, 2026

Study Completion (Estimated)

December 21, 2026

Study Registration Dates

First Submitted

July 29, 2023

First Submitted That Met QC Criteria

July 29, 2023

First Posted (Actual)

August 7, 2023

Study Record Updates

Last Update Posted (Actual)

August 7, 2023

Last Update Submitted That Met QC Criteria

July 29, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AML_Registry

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe